Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis
Jun Ho Yi, Sang Eun Yoon, Seok Jin Kim, Darae Kim, Jin-oh Choi, Ju-Hong Min, Byoung Joon Kim, Jung-Sun Kim, Jung Eun Lee, Junseok Jeon, Joon Young Choi, Kihyun Kim · 2026
Read Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis by Jun Ho Yi, Sang Eun Yoon, Seok Jin Kim, Darae Kim, Jin-oh Choi, Ju-Hong Min, Byoung Joon Kim, Jung-Sun Kim, Jung Eun Lee, Junseok Jeon, Joon Young Choi, Kihyun Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13562457.txt.
Description
Jun Ho Yi and eleven co-authors published a retrospective analysis in twenty twenty-six on daratumumab alone for relapsed AL amyloidosis. In this disease, abnormal proteins damage organs, and relapse is hard to treat because patients are already frail. The antibody is a mainstay in related conditions, so the center reviewed its own experience.
Forty patients from a prospective cohort received the drug by itself. Most had advanced-stage disease by standard criteria. About seventy-two percent responded in their blood markers and about forty-two percent in the heart. Median progression-free survival reached nearly twenty-two months, and treatment was generally tolerated. Deep responses predicted longer control, supporting the single drug as a real option at relapse.
Catalog record
| CREATOR | Jun Ho Yi, Sang Eun Yoon, Seok Jin Kim, Darae Kim, Jin-oh Choi, Ju-Hong Min, Byoung Joon Kim, Jung-Sun Kim, Jung Eun Lee, Junseok Jeon, Joon Young Choi, Kihyun Kim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |